Systemic Sclerosis - Pipeline Insight, 2024

This “Systemic Sclerosis - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Systemic Sclerosis Understanding

Systemic Sclerosis: Overview

Scleroderma, also known as Systemic Sclerosis, progressive systemic sclerosis or the CREST syndrome, is a chronic skin disorder that affects the skin, connective tissues and other internal organs. The disorder takes place sin humans, when the immune system causes the body to make the protein collagen, an important component of the skin, in huge amounts. Scleroderma is considered to be a rare disorder with an estimated prevalence of 276-300 cases per million, in United States and an incidence rate of about 20 cases per million per year. The systemic sclerosis is segmented into two subsets depending on the extent of skin involvement-localized scleroderma and systemic scleroderma. The most common sign that is observed in scleroderma is the Raynaud’s phenomenon, a clinical problem that is associated with cold and stress induced vasospasm of the digital arteries and cutaneous arterioles that are involved within the body’s thermoregulation. There is no particular test that is recommended in scleroderma for diagnosis. It is a clinical diagnosis which needs a thorough examination and history. Currently there is no cure that has been observed for scleroderma. Instead the treatment by a dermatologist focusses on the control and management of symptoms. As scleroderma tends to have many symptoms, a combinational approach might often be required for the treatment and management of symptoms in an effective manner.

Systemic Sclerosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Systemic Sclerosis pipeline landscape is provided which includes the disease overview and Systemic Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Systemic Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Sclerosis.

Systemic Sclerosis Emerging Drugs Chapters

This segment of the Systemic Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Sclerosis Emerging Drugs

Iloprost: Eicos Sciences Iloprost is a stable analogue of PGI2 and a potent prostacyclin (IP) receptor agonist. By mimicking PGI2, it is a vasodilator and inhibitor of platelet activation and fibrosis. Iloprost stimulates generation of c AMP by binding to the IP receptor, thereby affecting phospholipase activity and cytosolic calcium levels in platelets, fibroblasts, and endothelial cells. It is a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed and investigated in Phase III stage of development for the treatment of digital ischemic episodes in people with SystemicSclerosis(SSc).

ECCS 50: Cytori Therapeutics ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient’s fat tissue and reinjecting these cells into the hands. ECCS 50 are adipose derived stem and regenerative cells (ADRCs) taken from the patient’s own tissue and prepared using Cytori’s cellulation system before administration. ADRCs can be used to repair and regenerate a range of damaged or diseased tissue types by differentiation of the ASRCs along the specific cell lineage, thereby replacing the damaged or missing tissue.

Lenabasum (JBT-101): Corbus Pharmaceuticals Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles without evidence of immunosuppression.

EHP-101: Emerald Health Pharmaceuticals EHP-101 is an oral formulation of VCE-004.8, a synthetic aminoquinone derivative of CBD with dual peroxisome proliferator-activated receptor gamma (PPAR?) and cannabinoid receptor type 2 (CB2) agonist activity. Both receptors are therapeutic targets for SSc. EHP-101 also modulates the hypoxia inducible factor (HIF) pathway, expanding the rationale for its development as a novel SSc drug. It is currently in phase II stage of development and is being developed by Emerald Health Pharmaceuticals.

Systemic Sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Systemic Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Systemic Sclerosis

There are approx. 50+ key companies which are developing the therapies for Systemic Sclerosis. The companies which have their Systemic Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Eicos Sciences.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Systemic Sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Systemic Sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Sclerosis drugs.

Systemic Sclerosis Report Insights

• Systemic Sclerosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Systemic Sclerosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Systemic Sclerosis drugs?
• How many Systemic Sclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Sclerosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Systemic Sclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Systemic Sclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.